High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma

Daniel O. Persky, Craig Moskowitz, Alexander Filatov, Rakhee Saxena, Haiyan Cui, Julie Teruya-Feldstein

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

INTRODUCTION: Of about 20% of patients with relapsed/refractory Hodgkin lymphoma (HL), approximately half achieve long-term remissions after high-dose chemoradiotherapy and autologous stem cell transplantation (HDT/ASCT). Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear. We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance. METHODS: Pre-ICE biopsy specimens of 191 patients enrolled on 1 of 2 Institutional Review Board-approved clinical trials of HDT/ASCT. We performed immunohistochemistry staining for Bcl-2, Bax, Bim, p53, and interleukin-6. Samples were considered positive if more than 10% of Hodgkin Reed-Sternberg cells stained at any intensity. RESULTS: Ninety-one patients had sufficient tissue available. Forty-eight patients (53%) had an event and 36 (40%) died. Median event-free survival (EFS) was 8.5 years, median overall survival (OS) was not reached, and median follow-up was 8.8 years. Bcl-2 was overexpressed in 37/91 (41%), Bax in 28/65 (43%), Bim in 9/72 (13%), p53 in 38/89 (43%), and interleukin-6 in 58/84 (69%) patients. Overexpression of these biomarkers had no statistically significant association with EFS or OS, except for association of Bim overexpression with inferior OS (P=0.0385). The 3-factor clinical model (B symptoms at relapse, extranodal disease, and complete remission duration of <1 y) remained highly significant (0/1 vs. 2/3 factors) for EFS and OS (P=0.0008 and P=0.0001, respectively). CONCLUSIONS: Despite the evidence that p53 and Bcl-2 overexpression may predict a worse prognosis with initial treatment, it seems that at relapse such overexpression is either not prognostically significant, or that the treatment with ICE and HDT/ASCT overcomes its significance. Subsequent studies should further address the role of Bim in both initial and relapsed/refractory settings.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Chemoradiotherapy
Hodgkin Disease
Stem Cell Transplantation
Biomarkers
Ifosfamide
Carboplatin
Etoposide
Disease-Free Survival
Survival
Interleukin-6
Reed-Sternberg Cells
Recurrence
Research Ethics Committees
Therapeutics
Immunohistochemistry
Clinical Trials
Staining and Labeling
Biopsy
Drug Therapy

Keywords

  • Autologous stem cell transplant (ASCT)
  • Biomarkers
  • Chemoradiotherapy
  • Relapsed/refractory Hodgkin lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma. / Persky, Daniel O.; Moskowitz, Craig; Filatov, Alexander; Saxena, Rakhee; Cui, Haiyan; Teruya-Feldstein, Julie.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 18, No. 1, 01.01.2010, p. 35-40.

Research output: Contribution to journalArticle

Persky, Daniel O. ; Moskowitz, Craig ; Filatov, Alexander ; Saxena, Rakhee ; Cui, Haiyan ; Teruya-Feldstein, Julie. / High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma. In: Applied Immunohistochemistry and Molecular Morphology. 2010 ; Vol. 18, No. 1. pp. 35-40.
@article{2699a121e051418c84cf7e2558de37d8,
title = "High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma",
abstract = "INTRODUCTION: Of about 20{\%} of patients with relapsed/refractory Hodgkin lymphoma (HL), approximately half achieve long-term remissions after high-dose chemoradiotherapy and autologous stem cell transplantation (HDT/ASCT). Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear. We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance. METHODS: Pre-ICE biopsy specimens of 191 patients enrolled on 1 of 2 Institutional Review Board-approved clinical trials of HDT/ASCT. We performed immunohistochemistry staining for Bcl-2, Bax, Bim, p53, and interleukin-6. Samples were considered positive if more than 10{\%} of Hodgkin Reed-Sternberg cells stained at any intensity. RESULTS: Ninety-one patients had sufficient tissue available. Forty-eight patients (53{\%}) had an event and 36 (40{\%}) died. Median event-free survival (EFS) was 8.5 years, median overall survival (OS) was not reached, and median follow-up was 8.8 years. Bcl-2 was overexpressed in 37/91 (41{\%}), Bax in 28/65 (43{\%}), Bim in 9/72 (13{\%}), p53 in 38/89 (43{\%}), and interleukin-6 in 58/84 (69{\%}) patients. Overexpression of these biomarkers had no statistically significant association with EFS or OS, except for association of Bim overexpression with inferior OS (P=0.0385). The 3-factor clinical model (B symptoms at relapse, extranodal disease, and complete remission duration of <1 y) remained highly significant (0/1 vs. 2/3 factors) for EFS and OS (P=0.0008 and P=0.0001, respectively). CONCLUSIONS: Despite the evidence that p53 and Bcl-2 overexpression may predict a worse prognosis with initial treatment, it seems that at relapse such overexpression is either not prognostically significant, or that the treatment with ICE and HDT/ASCT overcomes its significance. Subsequent studies should further address the role of Bim in both initial and relapsed/refractory settings.",
keywords = "Autologous stem cell transplant (ASCT), Biomarkers, Chemoradiotherapy, Relapsed/refractory Hodgkin lymphoma",
author = "Persky, {Daniel O.} and Craig Moskowitz and Alexander Filatov and Rakhee Saxena and Haiyan Cui and Julie Teruya-Feldstein",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/PAI.0b013e3181b473b7",
language = "English (US)",
volume = "18",
pages = "35--40",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma

AU - Persky, Daniel O.

AU - Moskowitz, Craig

AU - Filatov, Alexander

AU - Saxena, Rakhee

AU - Cui, Haiyan

AU - Teruya-Feldstein, Julie

PY - 2010/1/1

Y1 - 2010/1/1

N2 - INTRODUCTION: Of about 20% of patients with relapsed/refractory Hodgkin lymphoma (HL), approximately half achieve long-term remissions after high-dose chemoradiotherapy and autologous stem cell transplantation (HDT/ASCT). Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear. We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance. METHODS: Pre-ICE biopsy specimens of 191 patients enrolled on 1 of 2 Institutional Review Board-approved clinical trials of HDT/ASCT. We performed immunohistochemistry staining for Bcl-2, Bax, Bim, p53, and interleukin-6. Samples were considered positive if more than 10% of Hodgkin Reed-Sternberg cells stained at any intensity. RESULTS: Ninety-one patients had sufficient tissue available. Forty-eight patients (53%) had an event and 36 (40%) died. Median event-free survival (EFS) was 8.5 years, median overall survival (OS) was not reached, and median follow-up was 8.8 years. Bcl-2 was overexpressed in 37/91 (41%), Bax in 28/65 (43%), Bim in 9/72 (13%), p53 in 38/89 (43%), and interleukin-6 in 58/84 (69%) patients. Overexpression of these biomarkers had no statistically significant association with EFS or OS, except for association of Bim overexpression with inferior OS (P=0.0385). The 3-factor clinical model (B symptoms at relapse, extranodal disease, and complete remission duration of <1 y) remained highly significant (0/1 vs. 2/3 factors) for EFS and OS (P=0.0008 and P=0.0001, respectively). CONCLUSIONS: Despite the evidence that p53 and Bcl-2 overexpression may predict a worse prognosis with initial treatment, it seems that at relapse such overexpression is either not prognostically significant, or that the treatment with ICE and HDT/ASCT overcomes its significance. Subsequent studies should further address the role of Bim in both initial and relapsed/refractory settings.

AB - INTRODUCTION: Of about 20% of patients with relapsed/refractory Hodgkin lymphoma (HL), approximately half achieve long-term remissions after high-dose chemoradiotherapy and autologous stem cell transplantation (HDT/ASCT). Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear. We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance. METHODS: Pre-ICE biopsy specimens of 191 patients enrolled on 1 of 2 Institutional Review Board-approved clinical trials of HDT/ASCT. We performed immunohistochemistry staining for Bcl-2, Bax, Bim, p53, and interleukin-6. Samples were considered positive if more than 10% of Hodgkin Reed-Sternberg cells stained at any intensity. RESULTS: Ninety-one patients had sufficient tissue available. Forty-eight patients (53%) had an event and 36 (40%) died. Median event-free survival (EFS) was 8.5 years, median overall survival (OS) was not reached, and median follow-up was 8.8 years. Bcl-2 was overexpressed in 37/91 (41%), Bax in 28/65 (43%), Bim in 9/72 (13%), p53 in 38/89 (43%), and interleukin-6 in 58/84 (69%) patients. Overexpression of these biomarkers had no statistically significant association with EFS or OS, except for association of Bim overexpression with inferior OS (P=0.0385). The 3-factor clinical model (B symptoms at relapse, extranodal disease, and complete remission duration of <1 y) remained highly significant (0/1 vs. 2/3 factors) for EFS and OS (P=0.0008 and P=0.0001, respectively). CONCLUSIONS: Despite the evidence that p53 and Bcl-2 overexpression may predict a worse prognosis with initial treatment, it seems that at relapse such overexpression is either not prognostically significant, or that the treatment with ICE and HDT/ASCT overcomes its significance. Subsequent studies should further address the role of Bim in both initial and relapsed/refractory settings.

KW - Autologous stem cell transplant (ASCT)

KW - Biomarkers

KW - Chemoradiotherapy

KW - Relapsed/refractory Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=76149111943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149111943&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181b473b7

DO - 10.1097/PAI.0b013e3181b473b7

M3 - Article

C2 - 19701081

AN - SCOPUS:76149111943

VL - 18

SP - 35

EP - 40

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 1

ER -